Announcement no. 8

Status communication: NGAL Patent – Fondsrådet (Danish Securities Council) – IR news

The NGAL patent and market estimate

BioPorto is pleased to announce the receipt of the PCT (Patent Cooperation Treaty) International Preliminary Report on Patentability regarding the NGAL PCT patent application. In this report, the PCT examiner has evaluated the claims in the application and finds them all to have novelty and inventive step, which means that the application is now well set to enter the national phase. The report is an important landmark in the patent application process, securing a solid base for the continuation of negotiations on licensing agreements for the NGAL intellectual property rights, the value of which has hereby been significantly increased.

In these negotiations, the estimated market size for the NGAL test is of great importance. As there are no other tests for the early diagnosis of kidney damage, the market potential of the NGAL test is huge. BioPorto’s expectation, in line with that of major diagnostic companies, is that the new NGAL test will be used in routine diagnostics several times a day on almost all patients admitted to intensive care units.

The worldwide market for a test for kidney damage leading to acute renal failure in patients undergoing intensive care is estimated to be 150-200 million tests per annum, representing a turnover of more than 1 billion US dollars per annum.

The NGAL ELISA kit, developed by BioPorto’s subsidiary AntibodyShop, is expected to achieve only a small market share in comparison with random-access and point-of-care tests; on the other hand, license revenue from the NGAL patent is expected to make up a major proportion of AntibodyShop's turnover in the years to come. The first license agreement is expected to be completed in April 2007.

Fondsrådet (Danish Securities Council) and accounting issues

Fondsrådet’s secretariat has informed BioPorto that the secretariat regards all outstanding matters concerning BioPorto and the issues raised with Erhvervsankenævnet (the Commercial Appeals Council) as settled. Furthermore, Erhvervsankenævnet has informed BioPorto that the matter is now closed.

Investor relations news

BioPorto has launched an IR newsletter which is issued to interested parties and published on the company's home page at the start of each month. The newsletter summarizes events of the previous month. The first newsletter, for January 2007, can be seen on www.bioporto.com.

For further information please contact:

Thea Olesen, CEO

Tel. +45 45 29 00 29, e-mail to@bioporto.com